AOD-9604
Anti-Obesity Drug 9604 · HGH Fragment 176-191
Popular for:Fat metabolism, weight loss, cartilage repair
0
Registered Trials
0
Trial Publications
11
PubMed References
Preclinical
Evidence Level
Overview
AOD-9604 is a modified fragment of the human growth hormone molecule, specifically amino acids 176-191 with an added tyrosine at the N-terminus. The short version: people usually care about it for fat metabolism, weight loss, cartilage repair, but the strength of the evidence depends heavily on indication and study type.
AOD-9604 is a modified fragment of the human growth hormone molecule, specifically amino acids 176-191 with an added tyrosine at the N-terminus. It was developed by Monash University in Australia to isolate the fat-metabolizing effects of HGH without its growth-promoting or diabetogenic properties.
AOD-9604 completed Phase IIb clinical trials for obesity but did not advance to Phase III due to insufficient efficacy at the doses tested. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar levels or cell proliferation.
Research Snapshot
What the evidence says
PreclinicalAOD-9604 currently shows 0 registered trials from ClinicalTrials.gov, 0 PubMed trial publications (0 RCT-tagged), and 11 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 0 registered trials are tracked from ClinicalTrials.gov intervention records.
- 0 PubMed clinical-trial publications are indexed.
- 0 PubMed randomized controlled trial publications are indexed.
- 11 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
AOD-9604 mimics the lipolytic mechanism of natural growth hormone by acting on beta-3 adrenergic receptors in adipose tissue.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
0
Registered Trials
0
Trial Publications
0
RCT Publications
11
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
0
Registered trials
0
Trial publications
0
RCT publications
11
PubMed references
5
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
AOD-9604
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceNot FDA-approved. FDA Category 2 (banned from compounding). Previously in clinical trials for obesity (Metabolic Pharmaceuticals, Australia). Potential Category 1 reinstatement under review.
Key PubMed References
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
PMID: 41490200Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026
PMID: 41966639Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
Thomas A, Görgens C, Guddat S, et al. · Journal of separation science · 2016
PMID: 26578461Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
Thevis M, Schänzer W · Journal of pharmaceutical and biomedical analysis · 2014
PMID: 24906629Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
Thevis M, Thomas A, Schänzer W · Expert review of proteomics · 2014
PMID: 25382550Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for AOD-9604 yet.
Side Effects & Safety
- Injection site reactions - Headache - Generally well-tolerated in clinical trials - Efficacy questioned due to Phase II results
Known Interactions
No curated interaction entry is live for AOD-9604 yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.